Across TCGA pan-cancer cohorts, MIR422A Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated MIR422A data layer compared with 9 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher MIR422A Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MIR422A expression acts as an unfavorable survival marker.

BLCA are the cancer types where MIR422A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	All	0.121	0.615	.002	18	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

Exploration

Same gene, other analysis: MIR422A tumor-vs-normal RNA expression · all MIR422A data types